Quick Answer
Spero Therapeutics, Inc. reported Total Revenue of $66.80 million for fiscal year 2025.
Spero Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $66.80M +39.2% |
$47.98M -53.8% |
$103.78M +94.0% |
$53.51M +193.1% |
$18.26M +95.7% |
$9.33M -48.6% |
| Revenue (ASC 606) | $12.59M +3292.5% |
$371.0K -60.2% |
$933.0K -62.7% |
$2.50M -18.5% |
$3.07M +1089.9% |
$258.0K -94.6% |
| Net Income | — | — | — | — | — | — |
| Diluted EPS | $0.15 +111.8% |
-$1.27 -395.3% |
$0.43 +135.0% |
-$1.23 +57.7% |
-$2.91 | — |
| Total Assets | $68.92M -37.7% |
$110.54M -39.4% |
$182.39M +46.1% |
$124.80M -27.0% |
$171.07M +11.5% |
$153.45M +44.6% |
| Cash and Equivalents | $40.27M -23.9% |
$52.89M -30.7% |
$76.33M -30.0% |
$109.11M -3.1% |
$112.58M +32.1% |
$85.21M +186.6% |
| Stockholders Equity | $59.02M +28.0% |
$46.12M -56.9% |
$106.89M +40.8% |
$75.93M -14.0% |
$88.29M -33.1% |
$132.04M +77.1% |
| R&D Expense | $38.47M -60.2% |
$96.76M +88.1% |
$51.44M +8.1% |
$47.59M -26.2% |
$64.53M -3.7% |
$67.00M +1.9% |
| Operating Income | $6.31M +108.6% |
-$73.36M -441.5% |
$21.48M +150.9% |
-$42.20M +52.0% |
-$87.97M -11.2% |
-$79.11M -25.1% |
| Shares Outstanding | 56.41M +3.3% |
54.59M +3.0% |
53.00M +1.0% |
52.46M +61.9% |
32.39M +10.7% |
29.26M +52.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.44M | -59.6% | -61.6% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2018 | -$10.46M | -6.4% | -5.1% |
| Diluted EPS | September 30, 2025 | -$0.13 | +59.4% | -333.3% |
| Total Assets | September 30, 2025 | $54.17M | -59.9% | -12.8% |
| Cash and Equivalents | September 30, 2025 | $48.62M | -36.3% | +55.9% |
| Stockholders Equity | September 30, 2025 | $26.49M | -59.6% | -19.3% |
| R&D Expense | September 30, 2025 | $8.60M | -68.0% | -19.4% |
| Operating Income | September 30, 2025 | -$7.92M | +57.4% | -223.9% |
| Shares Outstanding | September 30, 2025 | 56.31M | +3.7% | +0.2% |
- Spero Therapeutics, Inc. reported Total Revenue of $66.80 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +39.2% in Total Revenue compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Revenue (ASC 606) of $12.59 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +3292.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Net Income of -$41.66 million for fiscal year 2018.
- Spero Therapeutics, Inc. showed a decrease of -7.5% in Net Income compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Diluted EPS of $0.15 per share for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +111.8% in Diluted EPS compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Total Assets of $68.92 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed a decrease of -37.7% in Total Assets compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Cash and Equivalents of $40.27 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed a decrease of -23.9% in Cash and Equivalents compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Stockholders Equity of $59.02 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +28.0% in Stockholders Equity compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported R&D Expense of $38.47 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed a decrease of -60.2% in R&D Expense compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Operating Income of $6.31 million for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +108.6% in Operating Income compared to the prior fiscal year.
- Spero Therapeutics, Inc. reported Shares Outstanding of 56.41 million shares for fiscal year 2025.
- Spero Therapeutics, Inc. showed an increase of +3.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: